Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
8.16
0.00 (0.00%)
At close: Sep 16, 2025, 4:00 PM EDT
8.16
0.00 (0.00%)
After-hours: Sep 16, 2025, 4:00 PM EDT
Prothena Corporation Revenue
Prothena Corporation had revenue of $4.42M in the quarter ending June 30, 2025, a decrease of -96.65%. This brings the company's revenue in the last twelve months to $10.34M, down -95.24% year-over-year. In the year 2024, Prothena Corporation had annual revenue of $135.16M with 47.92% growth.
Revenue (ttm)
$10.34M
Revenue Growth
-95.24%
P/S Ratio
42.47
Revenue / Employee
$63,442
Employees
163
Market Cap
439.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRTA News
- 19 days ago - Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire
- 20 days ago - Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program - Business Wire
- 5 weeks ago - Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 6 weeks ago - Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 7 weeks ago - Prothena to Report Second Quarter 2025 Financial Results on August 4 - Business Wire
- 3 months ago - Prothena Announces Corporate Restructuring - Business Wire
- 3 months ago - Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Business Wire
- 4 months ago - Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga